Drug Profile
Cemdomespib - Biogen
Alternative Names: RTA 901Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator University of Kansas
- Developer Biogen
- Class 1 ring heterocyclic compounds; Acetamides; Analgesics; Anti-inflammatories; Biphenyl compounds; Ethers; Fluorobenzenes; Neuroprotectants; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic neuropathies
- Preclinical Inflammation; Neuropathic pain